Search

Your search keyword '"Björnebo, Lars"' showing total 21 results
Start Over Author "Björnebo, Lars"
21 results on '"Björnebo, Lars"'

1. Diagnosis of prostate cancer with magnetic resonance imaging in men treated with 5-alpha-reductase inhibitors

Author

Falagario, Ugo G., Lantz, Anna, Jambor, Ivan, Busetto, Gian Maria, Bettocchi, Carlo, Finati, Marco, Ricapito, Anna, Luzzago, Stefano, Ferro, Matteo, Musi, Gennaro, Totaro, Angelo, Racioppi, Marco, Carbonara, Umberto, Checcucci, Enrico, Manfredi, Matteo, D’Aietti, Damiano, Porcaro, Antonio Benito, Nordström, Tobias, Björnebo, Lars, Oderda, Marco, Soria, Francesco, Taimen, Pekka, Aronen, Hannu J., Perez, Ileana Montoya, Ettala, Otto, Marchioni, Michele, Simone, Giuseppe, Ferriero, Mariaconsiglia, Brassetti, Aldo, Napolitano, Luigi, Carmignani, Luca, Signorini, Claudia, Conti, Andrea, Ludovico, Giuseppe, Scarcia, Marcello, Trombetta, Carlo, Claps, Francesco, Traunero, Fabio, Montanari, Emanuele, Boeri, Luca, Maggi, Martina, Del Giudice, Francesco, Bove, Pierluigi, Forte, Valerio, Ficarra, Vincenzo, Rossanese, Marta, Mucciardi, Giuseppe, Pagliarulo, Vincenzo, Tafuri, Alessandro, Mirone, Vincenzo, Schips, Luigi, Antonelli, Alessandro, Gontero, Paolo, Cormio, Luigi, Sciarra, Alessandro, Porpiglia, Francesco, Bassi, PierFrancesco, Ditonno, Pasquale, Boström, Peter J., Messina, Emanuele, Panebianco, Valeria, De Cobelli, Ottavio, and Carrieri, Giuseppe

Published
2023
Full Text
View/download PDF

3. Prostate cancer incidence and mortality in men exposed to α1-adrenergic receptor antagonists.

Author

Björnebo, Lars, Razdan, Shirin, Discacciati, Andrea, Palsdottir, Thorgerdur, Aly, Markus, Nordström, Tobias, Eklund, Martin, Lundon, Dara, Grönberg, Henrik, Tewari, Ash, Wiklund, Peter, Kyprianou, Natasha, and Lantz, Anna

Subjects
*PROSTATE-specific antigen, *STATISTICAL models, *PROPORTIONAL hazards models, *BENIGN prostatic hyperplasia, *PROSTATE cancer patients, *PROSTATE cancer
Abstract

Background α1-Adrenergic receptor antagonists are commonly used to treat benign prostatic hyperplasia. Preclinical studies suggest that they induce cell death and inhibit tumor growth. This study evaluated the risk of prostate cancer death in men using α1-adrenergic receptor antagonists. Methods A population-based cohort study in Stockholm, Sweden (January 1, 2007, to December 31, 2019) included 451 779 men with a prostate-specific antigen test result. Study entry was 1 year after the first prostate-specific antigen test. Men were considered exposed at their second filled prescription. The primary outcome was prostate cancer mortality. Secondary outcomes were all-cause mortality and prostate cancer incidence. Cox proportional hazards regression models were used to calculate adjusted hazard ratios (HRs) and 95% confidence intervals (CIs) for all outcomes. Inverse-probability weighting with marginal structural models accounted for time-dependent confounders. Results Of 351 297 men in the final cohort, 39 856 (11.3%) were exposed to α1-adrenergic receptor antagonists. Median (interquartile range) follow-up for prostate cancer mortality was 8.9 (5.1-10.9) years; median (interquartile range) exposure time to α1-adrenergic receptor antagonists was 4.4 (2.0-7.6) years. There was no evidence of an association between α1-adrenergic receptor antagonist use and prostate cancer mortality, all-cause mortality, or high-grade prostate cancer. α1-Adrenergic receptor antagonist use was associated with an increased risk of prostate cancer (HR = 1.11, 95% CI = 1.06 to 1.17) and low-grade prostate cancer (HR = 1.22, 95% CI = 1.11 to 1.33). Men whose prostate cancer was treated with α1-adrenergic receptor antagonists underwent more frequent prostate-specific antigen testing. Conclusions Our findings show no significant association between α1-adrenergic receptor adrenoceptor antagonist exposure and prostate cancer mortality or high-grade prostate cancer. Although the preclinical evidence indicates a potential chemopreventive effect, this study's findings do not support it. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

4. Prostate Cancer Incidence and Mortality in Men Exposed to α1-Adrenoceptor Antagonists

Author

Björnebo, Lars, primary, Razdan, Shirin, additional, Discacciati, Andrea, additional, Palsdottir, Thorgerdur, additional, Aly, Markus, additional, Nordström, Tobias, additional, Eklund, Martin, additional, Lundon, Dara, additional, Grönberg, Henrik, additional, Tewari, Ash, additional, Wiklund, Peter, additional, Kyprianou, Natasha, additional, and Lantz, Anna, additional

Published
2024
Full Text
View/download PDF

5. PD29-12 THE IMPACT OF THE TIME ELAPSED BETWEEN PRIMARY TREATMENT AND BCR ON CANCER SPECIFIC MORTALITY IN PATIENTS WHO EXPERIENCED BCR AFTER PRIMARY TREATMENT

Author

Pellegrino, Francesco, primary, Falagario, Ugo G., additional, Abbadi, Ahmad, additional, Björnebo, Lars, additional, Valdman, Alexander, additional, Carrieri, Giuseppe, additional, Briganti, Alberto, additional, Montorsi, Francesco, additional, Akre, Olof, additional, Aly, Markus, additional, Eklund, Martin, additional, Nordström, Tobias, additional, Grönberg, Henrik, additional, Lantz, Anna, additional, and Wiklund, Peter, additional

Published
2024
Full Text
View/download PDF

7. Biochemical Recurrence and Risk of Mortality Following Radiotherapy or Radical Prostatectomy

Author

Falagario, Ugo Giovanni, primary, Abbadi, Ahmad, additional, Remmers, Sebastiaan, additional, Björnebo, Lars, additional, Bogdanovic, Darko, additional, Martini, Alberto, additional, Valdman, Alexander, additional, Carrieri, Giuseppe, additional, Menon, Mani, additional, Akre, Olof, additional, Eklund, Martin, additional, Nordström, Tobias, additional, Grönberg, Henrik, additional, Lantz, Anna, additional, and Wiklund, Peter, additional

Published
2023
Full Text
View/download PDF

9. PD15-04 PREDICTION OF PROSTATE CANCER SPECIFIC MORTALITY IN MEN UNDERGOING RADIOTHERAPY WITH OR WITHOUT HORMONAL TREATMENT, RISK STRATIFICATION BASED ON CLINICAL CHARACTERISTICS AND PSA TREATMENT RESPONSE

Author

Falagario, Ugo, primary, Bogdanovic, Darko, additional, Björnebo, Lars, additional, Abbadi, Ahmad, additional, Valdman, Alexander, additional, Eklund, Martin, additional, Nordström, Tobias, additional, Aly, Markus, additional, Grönberg, Henrik, additional, Wiklund, Peter, additional, and Lantz, Anna, additional

Published
2023
Full Text
View/download PDF

10. MP17-06 VALIDATION OF EAU RISK GROUPS FOR BIOCHEMICAL RECURRENCE AFTER RADIOTHERAPY AND RADICAL PROSTATECTOMY FOR PREDICTION OF PROSTATE CANCER MORTALITY

Author

Falagario, Ugo, primary, Bogdanovic, Darko, additional, Björnebo, Lars, additional, Abbadi, Ahmad, additional, Valdman, Alexander, additional, Eklund, Martin, additional, Nordström, Tobias, additional, Aly, Markus, additional, Grönberg, Henrik, additional, Lantz, Anna, additional, and Wiklund, Peter, additional

Published
2023
Full Text
View/download PDF

11. Biochemical Recurrence and Risk of Mortality Following Radiotherapy or Radical Prostatectomy

Author

Falagario, Ugo Giovanni, Abbadi, Ahmad, Remmers, Sebastiaan, Björnebo, Lars, Bogdanovic, Darko, Martini, Alberto, Valdman, Alexander, Carrieri, Giuseppe, Menon, Mani, Akre, Olof, Eklund, Martin, Nordström, Tobias, Grönberg, Henrik, Lantz, Anna, Wiklund, Peter, Falagario, Ugo Giovanni, Abbadi, Ahmad, Remmers, Sebastiaan, Björnebo, Lars, Bogdanovic, Darko, Martini, Alberto, Valdman, Alexander, Carrieri, Giuseppe, Menon, Mani, Akre, Olof, Eklund, Martin, Nordström, Tobias, Grönberg, Henrik, Lantz, Anna, and Wiklund, Peter

Abstract

Importance: Stratifying patients with biochemical recurrence (BCR) after primary treatment for prostate cancer based on the risk of prostate cancer-specific mortality (PCSM) is essential for determining the need for further testing and treatments. Objective: To evaluate the association of BCR after radical prostatectomy or radiotherapy and its current risk stratification with PCSM. Design, Setting, and Participants: This population-based cohort study included a total of 16 311 male patients with 10 364 (64%) undergoing radical prostatectomy and 5947 (36%) undergoing radiotherapy with curative intent (cT1-3, cM0) and PSA follow-up in Stockholm, Sweden, between 2003 and 2019. Follow-up for all patients was until death, emigration, or end of the study (ie, December 31, 2018). Data were analyzed between September 2022 and March 2023. Main Outcomes and Measures: Primary outcomes of the study were the cumulative incidence of BCR and PCSM. Patients with BCR were stratified in low- and high-risk according to European Association of Urology (EAU) criteria. Exposures: Radical prostatectomy or radiotherapy. Results: A total of 16 311 patients were included. Median (IQR) age was 64 (59-68) years in the radical prostatectomy cohort (10 364 patients) and 69 (64-73) years in the radiotherapy cohort (5947 patients). Median (IQR) follow-up for survivors was 88 (55-138) months and 89 (53-134) months, respectively. Following radical prostatectomy, the 15-year cumulative incidences of BCR were 16% (95% CI, 15%-18%) for the 4024 patients in the low D'Amico risk group, 30% (95% CI, 27%-32%) for the 5239 patients in the intermediate D'Amico risk group, and 46% (95% CI, 42%-51%) for 1101 patients in the high D'Amico risk group. Following radiotherapy, the 15-year cumulative incidences of BCR were 18% (95% CI, 15%-21%) for the 1230 patients in the low-risk group, 24% (95% CI, 21%-26%) for the 2355 patients in the intermediate-risk group, and 36% (95% CI, 33%-39%) for the 2362 patients in

Published
2023

13. Are We Ready to Implement Molecular Subtyping of Bladder Cancer in Clinical Practice? Part 2: Subtypes and Divergent Differentiation

Author

Sanguedolce, Francesca, primary, Zanelli, Magda, additional, Palicelli, Andrea, additional, Ascani, Stefano, additional, Zizzo, Maurizio, additional, Cocco, Giorgia, additional, Björnebo, Lars, additional, Lantz, Anna, additional, Landriscina, Matteo, additional, Conteduca, Vincenza, additional, Falagario, Ugo Giovanni, additional, Cormio, Luigi, additional, and Carrieri, Giuseppe, additional

Published
2022
Full Text
View/download PDF

14. Are We Ready to Implement Molecular Subtyping of Bladder Cancer in Clinical Practice? Part 1: General Issues and Marker Expression

Author

Sanguedolce, Francesca, primary, Zanelli, Magda, additional, Palicelli, Andrea, additional, Ascani, Stefano, additional, Zizzo, Maurizio, additional, Cocco, Giorgia, additional, Björnebo, Lars, additional, Lantz, Anna, additional, Falagario, Ugo Giovanni, additional, Cormio, Luigi, additional, and Carrieri, Giuseppe, additional

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results